Summary
I have discussed the pharmacokinetics, efficacies, and side effects of the various nonnarcotic drugs available for the treatment of patients who have headache. Sumatriptan, the newest one, is expensive but may be cost-effective for those who have failed traditional migraine treatment, who visit the ER frequently, who have potential for drug abuse, or who have to miss time from school or work due to the headache. Studies are in progress to compare sumatriptan with other available drugs such as DHE-45 and to determine its possible role in the prophylaxis of migraine. A new 5-HTID receptor agonist with more efficacy and fewer side effects may be developed in the future. When sumatriptan and DHE-45 are contraindicated due to hypertension or coronary artery disease, other drugs such as metoclopramide, ketorolac, and butorphanol can be used as alternatives.
Similar content being viewed by others
References
Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. JAMA. 1992;267:64–9.
Osterhaus JT, Autterman DL, Plachetka JR. Healthcare resource and lost labor costs of migraine headache in the United States. Pharmaco Economics. 1992;2:67–76.
Mathew NT. Transformed migraine. Cephalalgia. 1993;13(suppl 12):78–83.
Schulman EA, Silberstein SD. Symptomatic and prophylactic treatment of migraine and tension-type headache. Neurology. 1992;42(suppl 2):16–21.
Caekebeke JFV, Ferrari MD, Zwetsloot CP, Jansen J, Saxena PR. Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks. Neurology. 1992;42:1522–6.
Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci. 1992;13:307–11.
Fowler PA, Lacey LF, Thomas M, et al. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol. 1991;31:291–4.
The sumatriptan Auto-injector Study Group. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. Eur Neurol. 1991;31:323–31.
Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothcrock JF, Skaggs H Jr. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991;265:2831–5.
Fowler PA, Lacey LF, Keene ON, Thomas M. Effect of prophylactic migraine medications on the pharmacokinetic and pharmacodynamic profiles of sumatriptan. Cephalalgia. 1991;11:228–9.
Scott AK, Walley T, Breckenridge AM, Lacey LF, Fowler PA. Lack of an interaction between propranolol and sumatriptan. Br J Clin Pharmacol. 1991;32:581–4.
Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, Cranial neuralgias and facial pain. Cephalalgia 1988;8(suppl 7):19–36.
The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991;325:316–21.
Ensink FBM. Subcutaneous sumatriptan in the acute treatment of migraine. J Neurol. 1991;238:566–9.
Mathew NT, Dexter J, Couch J, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. U.S. Sumatriptan Research Group. Arch Neurol. 1992;49:1271–6.
The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group. A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. Eur Neurol. 1991;31:332–8.
Goadsby PJ, Zagami AS, Donnan GA, et al. Oral sumatriptan in acute migraine. Lancet. 1991;338:782–3.
Patten JP. Clinical experience with oral sumatriptan: a placebo-controlled, dose-ranging study. J Neurol. 1991;238:562–5.
The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and cafergot in the acute treatment of migraine. Eur Neurol. 1991;31:314–22.
The Oral Sumatriptan and Aspirin Plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol. 1992;32:177–84.
The Sumatriptan Cluster Headache Study Group. Treatment of acute cluster headache with sumatriptan. N Engl J Med. 1991;325:322–6.
Ekbom K, Monstad I, Prusinsi A, Cole JA, Pilgrim AJ, Noronha D. Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. Acta Neurol Scand. 1993;88:63–9.
Brown EG, Endersby CA, Smith RN, Talbot JCC. The safety and tolerability of sumatriptan: an overview. Eur Neurol. 1991;31:339–44.
Willett F, Curzen N, Adams J, Armitage M. Coronary vasospasm induced by subcutaneous sumatriptan. BMJ. 1992;304:1415.
Curtin T, Brook AP, Roberts J. Cardiorespiratory distress after sumatriptan given by injection. BMJ. 1992;305:713–4.
Inman W, Kubota K. Cardiorespiratory distress after sumatriptan given by injection. BMJ. 1992;305:714.
Lloyd DK, Pilgrim AJ. The safety of sumatriptan in asthmatic migraineurs. Cephalalgia 1993;13:201–4.
Ottervanger JP, Paalman HJA, Boxma GL, Strieker BH. Transmural myocardial infarction with sumatriptan. Lancet. 1993;341:861–2.
McCarthy BG, Peroutka SJ. Comparative neuropharmacology of dihydroergotamine and sumatriptan (GR43175). Headache. 1989;29:420–2.
Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36:995–7.
Callahan M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache. 1986;26:168–71.
Belgrade MJ, Ling LJ, Schleevogt MB, Ettinger MG, Ruiz E. Comparison of a single dose meperidine, butorphanol, and dihydroer-gotamine in the treatment of vascular headache. Neurology. 1989;39:590–2.
Bell R, Montoya D, Shnaib A, Lee AM. A comparative trial of three agents in the treatment of acute migraine headache. Ann Emerg Med. 1990;19:1079–82.
Saadah HA. Abortive headache therapy with intramuscular dihydroergotamine. Headache. 1992;32:18–20.
Klapper JA, Stanton J. Clinical experience with patient administered subcutaneous dihydroergotamine mesylate in refractory headaches. Headache. 1992;32:21–3.
Bousser MG, Loria Y. Efficacy of dihydroergotamine nasal spray in the acute treatment of migraine attacks. Cephalalgia. 1985;5(suppl 3):554–5.
DiSerio F, Patin J, Friedman A. USA trials of dihydroergotamine nasal spray in the acute treatment of migraine headache. Cephalalgia. 1989;9(suppl 10):344–5.
Krause KH, Bleicher MA. Dihydroergotamine nasal spray in the treatment of migraine attacks. Cephalalgia. 1985;5(suppl 3):138–9.
Massiou H. Dihydroergotamine nasal spray in prevention and treatment of migraine attacks: two controlled trials versus placebo. Cephalalgia. 1987;7(suppl 6):440–1.
Paiva T, Esperanca P, Marcelino L, Assis G. A double-blind trial with dihydroergotamine spray in migraine crisis. Cephalalgia. 1985;5(suppl 3):140–1.
Rohr J, Dufresne JJ. Dihydroergotamine nasal spray for the treatment of migraine attacks: a comparative double-blind crossover study with placebo. Cephalalgia. 1985;5(suppl 3):142–3.
Tulunay FC, Karan O, Aydin N, Culcuoglu A, Guvener A. Dihydroergotamine nasal spray during migraine attacks: a double-blind crossover study with placebo. Cephalalgia. 1987;7:131–3.
Mondell B, DiSerio F, Friedman A. Dihydroergotamine nasal spray in the acute treatment of migraine headache [abstract]. Clin Pharmacol Ther. 1989;45:161.
Tek DS, McClellan DS, Olshaker JS, Allen CL, Arthur DC. A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department. Ann Emerg Med. 1990;19:1083–7.
Ellis GL, Delaney J, DeHart DA, Owens A. The efficacy of metoclopramide in the treatment of migraine. Ann Emerg Med. 1993;22:191–5.
Pages LJ, Martinez JJ, Garg DC, et al. Pharmacokinetics of ketorolac tromethamine in hepatically impaired US young healthy subjects [abstract]. J Clin Pharmacol. 1983;27:324.
Stansk DR, Cherry C, Bradley R, Sarnquist FH, Yee JP. Efficacy and safety of single doses of intramuscular ketorolac tromethamine compared with meperidine for post-operative pain. Pharmacotherapy. 1990;10:405–45.
Brown CR, Moodie JE, Evans SA, et al. Efficacy of intramuscular ketorolac and meperidine in pain following major oral surgery [abstract]. Clin Pharmacol Ther. 1988;43:161.
Spindler JS, Mehlisch D, Brown CR. Intramuscular ketorolac and morphine in the treatment of moderate to severe pain after major surgery. Pharmacotherapy. 1990;10:515–85.
Harden RN, Carter TD, Gillman CS, Gross AJ, Peters JR. Ketorolac in acute headache management. Headache. 1991;31:463–4.
Klapper JA, Stanton JS. Ketorolac versus DHE and metoclopramide in the treatment of migraine headaches. Headache. 1991;31:523–4.
Turkewitz LJ, Sadaly JS, Dawson GA, et al. Self-administration of parenteral ketorolac tromethamine for head pain. Headache. 1992;32:452–4.
Larkin GL, Prescott JE. A randomized, double-blind, comparative study of the efficacy of ketorolac tromethamine versus meperidine in the treatment of severe migraine. Ann Emerg Med. 1992;21:919–24.
Duarte C, Dunaway F, Turner L, Aldag J, Frederick R. Ketorolac versus meperidine and hydroxyzine in the treatment of acute migraine headache: a randomized, prospective, double-blind trial. Ann Emerg Med. 1992;21:1116–21.
Koffer H, Hildebrand J III, Connell M. Potential for non-narcotic analgesics to save personnel costs associated with controlling injectable morphine and meperidine. Am J Hosp Pharm. 1990;47:1084–8.
Elenbaas RM, Iacono CU, Koellner KJ, et al. Dose effectiveness and safety of butorphanol in acute migraine headache. Pharmacotherapy. 1991;11:56–63.
Diamond S, Freitag FG, Diamond ML, Urban G. Transnasal butorphanol in the treatment of migraine headache pain. Headache Q. 1992;3:164–71.
Sicuteri F, Fusco BM, Marabini S, et al. Beneficial effect of capsaicin application to the nasal mucosa in cluster headache. Clin J Pain. 1989;5:49–53.
Fusco BM, Geppetti P, Fanciullacci M, Sicuteri F. Local application of capsaicin for the treatment of cluster headache and idiopathic trigeminal neuralgia. Cephalalgia. 1991;11(suppl 11):234–5.
Marks DR, Rappaport A, Padla D, et al. A double-blind placebo-controlled trial of intranasal capsaicin for cluster headache. Cephalalgia. 1993;13:114–6.
Sicuteri F, Raino I, Geppetti P. Substance P and endogenous opioid: how and where they could play a role in cluster headache. Cephalalgia. 1983;3(suppl 1):143–5.
Geppetti P, Fusco BM, Marabini S, et al. Secretion, pain and sneezing induced by the application of capsaicin to the nasal mucosa in man. Br J Pharmacol. 1988;93:509–14.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kumar, K.L. Recent advances in the acute management of migraine and cluster headaches. J Gen Intern Med 9, 339–348 (1994). https://doi.org/10.1007/BF02599185
Issue Date:
DOI: https://doi.org/10.1007/BF02599185